Accueil > Actualité
Actualite financiere : Actualite bourse

GlaxoSmithKline: rare disease drug shows positive results

( - GlaxoSmithKline on Wednesday said that its drug Nucala was the first treatment to show a significant reduction in flares for patients with hypereosinophilic syndrome, a rare inflammatory disorder.

A phase 3 study met its primary endpoint, demonstrating a statistically significant result with 50% fewer patients experiencing a worsening of symptoms requiring an escalation in therapy when treated with mepolizumab compared to placebo, the British drugmaker said.

Hypereosinophilic syndrome, which affects approximately 20,000 people globally, is characterised by an overproduction of eosinophils, a type of white blood cell, causing inflammation and organ damage.

Copyright (c) 2019 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.